These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 21469976

  • 1. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
    Ayllon J, Beuselinck B, Morel A, Barrascout E, Medioni J, Scotte F, Oudard S.
    Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L.
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [Abstract] [Full Text] [Related]

  • 3. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 4. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A.
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [Abstract] [Full Text] [Related]

  • 5. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS, Syrigos KN.
    BioDrugs; 2009 Sep; 23(6):377-89. PubMed ID: 19894779
    [Abstract] [Full Text] [Related]

  • 6. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 7. Targeted Therapy for Renal Cell Carcinoma.
    Joshi R, Rawal S.
    JNMA J Nepal Med Assoc; 2015 Jan; 53(198):83-8. PubMed ID: 26994026
    [Abstract] [Full Text] [Related]

  • 8. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
    Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A.
    Ann Oncol; 2015 Jun; 26(6):1118-1123. PubMed ID: 25701452
    [Abstract] [Full Text] [Related]

  • 9. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V.
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
    Guida FM, Santoni M, Conti A, Burattini L, Savini A, Zeppola T, Caricato M, Cascinu S, Tonini G, Santini D.
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):208-17. PubMed ID: 25151214
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
    Grünwald V, Desar IM, Haanen J, Fiedler W, Mouritzen U, Olsen MW, van Herpen CM.
    Acta Oncol; 2011 Jan; 50(1):121-6. PubMed ID: 21174612
    [Abstract] [Full Text] [Related]

  • 15. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V.
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [Abstract] [Full Text] [Related]

  • 16. [Pre- surgical therapy with sunitinib for adrenal metastasis from renal cell carcinoma : a case report].
    Inoue T, Murota T, Masuda T, Nishida T, Kawakita S, Kinoshita H, Matsuda T.
    Hinyokika Kiyo; 2013 Sep; 59(9):573-7. PubMed ID: 24113755
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.
    J Clin Oncol; 2008 Aug 01; 26(22):3743-8. PubMed ID: 18669461
    [Abstract] [Full Text] [Related]

  • 18. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.
    Stroup SP, Raheem OA, Palazzi KL, Liss MA, Mehrazin R, Kopp RP, Patel N, Cohen SA, Park SK, Patterson AL, Kane CJ, Millard F, Derweesh IH.
    Urology; 2013 Apr 01; 81(4):805-11. PubMed ID: 23414694
    [Abstract] [Full Text] [Related]

  • 19. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.
    Wolter P, Beuselinck B, Pans S, Schöffski P.
    Acta Oncol; 2009 Apr 01; 48(4):621-4. PubMed ID: 19107622
    [No Abstract] [Full Text] [Related]

  • 20. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S.
    Eur Urol; 2011 Dec 01; 60(6):1163-70. PubMed ID: 21802830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.